A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive

NCT06433921 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma
Mild Asthma

Interventions

DRUG: Salbutamol HFA-152a
DRUG: Salbutamol HFA-134a
DRUG: Placebo

Sponsor

GlaxoSmithKline